NCT05240690

Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies

Clinical Study on the Safety and Efficacy of Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies：HCCSC AB04 Trial

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 27 (estimated)
• Sponsor: Zhou Fuxiang · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety of MAK immune cells derived from umbilical cord blood combined with second-line treatments for hepatobiliary and pancreatic malignancies.And to investigate the initial efficacy of MAK immune cells derived from umbilical cord blood combined with second-line treatments for hepatobiliary and pancreatic malignancies.

Conditions

• Stage IV Pancreatic Cancer
• Hepatocellular Carcinoma , Cholangiocarcinoma

Interventions

Type	Name	Description
BIOLOGICAL	Umbilical Cord Blood Derived MAK Immune Cells	Intravenous drip

Timeline

• Start date: 2022-02-07
• Primary completion: 2023-12-31
• Completion: 2024-12-31
• First posted: 2022-02-15
• Last updated: 2022-02-15

Locations

1 site across 1 country: China